Autoimmune Neuromuscular Disorders

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2012 Mar 2

PMID 22379454

Citations 4

Authors

Jessica Kraker

Sasa A Zivkovic

Affiliations

Soon will be listed here.

Abstract

Autoimmune neuromuscular disorders affecting peripheral nerves, neuromuscular junction or muscle have a wide clinical spectrum with diverse pathogenetic mechanisms. Peripheral nervous system may be targeted in the context of complex immune reactions involving different cytokines, antigen-presenting cells, B cells and different types of T cells. Various immunomodulating and cytotoxic treatments block proliferation or activation of immune cells by different mechanisms attempting to control the response of the immune system and limit target organ injury. Most treatment protocols for autoimmune neuromuscular disorders are based on the use of corticosteroids, intravenous immunoglobulins and plasmapheresis, with cytotoxic agents mostly used as steroid-sparing medications. More recently, development of specific monoclonal antibodies targeting individual cell types allowed a different approach targeting specific immune pathways, but these new treatments are also associated with various adverse effects and their long-term efficacy is still unknown.

Citing Articles

Decoding Neuromuscular Disorders Using Phenotypic Clusters Obtained From Co-Occurrence Networks.

Diaz-Santiago E, Claros M, Yahyaoui R, de Diego-Otero Y, Calvo R, Hoenicka J Front Mol Biosci. 2021; 8:635074.

PMID: 34046427 PMC: 8147726. DOI: 10.3389/fmolb.2021.635074.

Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back.

Buscara L, Gross D, Daniele N J Pers Med. 2020; 10(4).

PMID: 33260623 PMC: 7768510. DOI: 10.3390/jpm10040258.

Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders.

Tichy E, Prosser B, Doyle D J Pharm Pract. 2020; 35(1):106-119.

PMID: 32677504 PMC: 8822190. DOI: 10.1177/0897190020938212.

Unusual reactions to hymenoptera stings: what should we keep in mind?.

Mingomataj E, Bakiri A, Ibranji A, Sturm G Clin Rev Allergy Immunol. 2014; 47(1):91-9.

PMID: 24962710 DOI: 10.1007/s12016-014-8434-y.

References

Kupersmith M . Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009; 256(8):1314-20. DOI: 10.1007/s00415-009-5120-8. View

Burns T, Dyck P, Aksamit A, Dyck P . The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases. J Neurol Sci. 2006; 244(1-2):77-87. DOI: 10.1016/j.jns.2006.01.014. View

. Assessment of plasmapheresis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1996; 47(3):840-3. View

Lozeron P, Denier C, Lacroix C, Adams D . Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009; 66(4):490-7. DOI: 10.1001/archneurol.2009.11. View

Dyck P, OBrien P, Swanson C, Low P, Daube J . Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985; 35(8):1173-6. DOI: 10.1212/wnl.35.8.1173. View

Maurer M, Toyka K, Gold R . Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscul Disord. 2002; 12(4):405-14. DOI: 10.1016/s0960-8966(01)00302-9. View

Viala K, Renie L, Maisonobe T, Behin A, Neil J, Leger J . Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain. 2004; 127(Pt 9):2010-7. DOI: 10.1093/brain/awh222. View

Gorson K, Ropper A . Positive salivary gland biopsy, Sjögren syndrome, and neuropathy: clinical implications. Muscle Nerve. 2003; 28(5):553-60. DOI: 10.1002/mus.10470. View

Gondim F, Brannagan 3rd T, Sander H, Chin R, Latov N . Peripheral neuropathy in patients with inflammatory bowel disease. Brain. 2005; 128(Pt 4):867-79. DOI: 10.1093/brain/awh429. View

10.

Vedeler C, Antoine J, Giometto B, Graus F, Grisold W, Hart I . Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006; 13(7):682-90. DOI: 10.1111/j.1468-1331.2006.01266.x. View

11.

Dalakas M . Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002; 59(12 Suppl 6):S13-21. DOI: 10.1212/wnl.59.12_suppl_6.s13. View

12.

Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G . Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000; 123 ( Pt 4):710-7. DOI: 10.1093/brain/123.4.710. View

13.

van Asseldonk J, Franssen H, Van den Berg-Vos R, Wokke J, van den Berg L . Multifocal motor neuropathy. Lancet Neurol. 2005; 4(5):309-19. DOI: 10.1016/S1474-4422(05)70074-0. View

14.

Lehmann H, Hartung H, Hetzel G, Stuve O, Kieseier B . Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol. 2006; 63(8):1066-71. DOI: 10.1001/archneur.63.8.1066. View

15.

Meriggioli M, Sanders D . Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8(5):475-90. PMC: 2730933. DOI: 10.1016/S1474-4422(09)70063-8. View

16.

Oh S, Kim D, Head T, Claussen G . Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1997; 20(9):1146-52. DOI: 10.1002/(sici)1097-4598(199709)20:9<1146::aid-mus9>3.0.co;2-8. View

17.

Stern B, Aksamit A, Clifford D, Scott T . Neurologic presentations of sarcoidosis. Neurol Clin. 2009; 28(1):185-98. DOI: 10.1016/j.ncl.2009.09.012. View

18.

Hirst C, Raasch S, Llewelyn G, Robertson N . Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry. 2006; 77(6):800-2. PMC: 2077476. DOI: 10.1136/jnnp.2005.076869. View

19.

Skeie G, Apostolski S, Evoli A, Gilhus N, Hart I, Harms L . Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2006; 13(7):691-9. DOI: 10.1111/j.1468-1331.2006.01476.x. View

20.

Caress J, Hobson-Webb L, Passmore L, Finkbiner A, Cartwright M . Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol. 2009; 256(3):339-42. DOI: 10.1007/s00415-009-0969-0. View